Evidence map›Paper›PMID 38607077›Full record

ReviewCells2024

Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus.

Caroline M Finn, K Kai McKinstry

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Tracheobronchial ulcers caused byThe Journal of international medical research · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Caroline M FinnImmunity and Pathogenesis Division, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
K Kai McKinstryImmunity and Pathogenesis Division, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0002-5038-7229
University of Central Florida · US

Funding

Harnessing type I interferon to promote lung-resident memory CD4 T cell immunity against influenzaR01AI167994 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI MCKINSTRY, KARL KAI · 2022 to 2025
$1.9M
Optimizing functional synergies between local and systemic memory CD4 T cell responses to influenzaR21AI148882 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI MCKINSTRY, KARL KAI · 2021 to 2022
$411k
Control of CD4 T cell effector function and tissue-resident memory fate by the transcription factor EomesR21AI146647 · NIAID · UNIVERSITY OF CENTRAL FLORIDA · PI MCKINSTRY, KARL KAI · 2019 to 2020
$410k
NIAID NIH HHS R01 AI167994NIAID NIH HHS R21 AI146647NIAID NIH HHS R21 AI148882NIH HHS AI146647NIH HHS AI148882NIH HHS AI167994
6 · The paper itself

Abstract

Current Influenza A virus (IAV) vaccines, which primarily aim to generate neutralizing antibodies against the major surface proteins of specific IAV strains predicted to circulate during the annual 'flu' season, are suboptimal and are characterized by relatively low annual vaccine efficacy. One approach to improve protection is for vaccines to also target the priming of virus-specific T cells that can protect against IAV even in the absence of preexisting neutralizing antibodies. CD4 T cells represent a particularly attractive target as they help to promote responses by other innate and adaptive lymphocyte populations and can also directly mediate potent effector functions. Studies in murine models of IAV infection have been instrumental in moving this goal forward. Here, we will review these findings, focusing on distinct subsets of CD4 T cell effectors that have been shown to impact outcomes. This body of work suggests that a major challenge for next-generation vaccines will be to prime a CD4 T cell population with the same spectrum of functional diversity generated by IAV infection. This goal is encapsulated well by the motto '

Indexed as

Influenza A virusInfluenza, HumanInfluenza VaccinesAnimalsAntibodies, NeutralizingCD4-Positive T-LymphocytesHumansMiceVaccinesAntibodies, NeutralizingInfluenza VaccinesVaccinesCD4 T cellcytotoxic CD4 T cellfollicular helper cellinfluenza virusregulatory CD4 T cellTh1Th17

Identifiers

PMID38607077
PMCPMC11012043
OpenAlexW4393994534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.